Fig. 8
RSL1D1 Is a Potential Molecular Target for Colorectal Cancer Treatment. Nude mice bearing HCT116p53+/+ or HCT116p53−/− tumors were randomly grouped and treated diebus tertius for 15 days with siNC or siRSL1D1 by intratumor transfection. A Western blot analysis of the amount of RSL1D1 protein in siRSL1D1- or siNC-treated tumors at the end of a 15-day treatment course. B Images of tumors from mice sacrificed at day 15. C Mean tumor volumes in each group during a 15-day treatment course. Data are represented as mean ± SD, n = 5. Student’s t test. *P < 0.05 and **P < 0.01 denote significant difference. D Representative images of tumor tissues revealed by H&E staining. Scale bars: 50 μm